{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:36:58Z","timestamp":1787697418782,"version":"build-2784847793"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00063-022-00911-x","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T17:29:39Z","timestamp":1648229379000},"page":"191-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CRP-Apherese bei akutem Myokardinfarkt bzw. COVID-19","CRP apheresis in acute myocardial infarction and COVID-19"],"prefix":"10.1007","volume":"117","author":[{"given":"Michael","family":"Buerke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sheriff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph D.","family":"Garlichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"911_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1253\/circj.CJ-18-0063","volume":"82","author":"T Anzai","year":"2018","unstructured":"Anzai\u00a0T (2018) Inflammatory mechanisms of cardiovascular remodeling. Circ\u00a0J 82:629\u2013635. https:\/\/doi.org\/10.1253\/circj.CJ-18-0063","journal-title":"Circ J"},{"key":"911_CR2","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1161\/01.STR.0000089920.93927.A7","volume":"34","author":"JF Arenillas","year":"2003","unstructured":"Arenillas\u00a0JF, \u00c1lvarez-Sab\u00edn\u00a0J, Molina\u00a0CA et al (2003) C\u2011reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 34:2463\u20132468. https:\/\/doi.org\/10.1161\/01.STR.0000089920.93927.A7","journal-title":"Stroke"},{"key":"911_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1124\/jpet.102.040600","volume":"303","author":"TD Barrett","year":"2002","unstructured":"Barrett\u00a0TD, Hennan\u00a0JK, Marks\u00a0RM, Lucchesi\u00a0BR (2002) C\u2011reactive-protein-associated increase in myocardial infarct size after ischemia\/reperfusion. J\u00a0Pharmacol Exp Ther 303:1007\u20131013. https:\/\/doi.org\/10.1124\/jpet.102.040600","journal-title":"J Pharmacol Exp Ther"},{"key":"911_CR4","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/oxfordjournals.eurheartj.a015180","volume":"18","author":"JT Beranek","year":"1997","unstructured":"Beranek\u00a0JT (1997) C\u2011reactive protein and complement in myocardial infarction and postinfarction heart failure. Eur Heart\u00a0J 18:1834\u20131835. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a015180","journal-title":"Eur Heart J"},{"key":"911_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1159\/000506176","volume":"49","author":"D Boljevic","year":"2020","unstructured":"Boljevic\u00a0D, Nikolic\u00a0A, Rusovic\u00a0S et al (2020) A promising innovative treatment for ST-elevation myocardial infarction: the use of C\u2011reactive protein selective apheresis: case report. Blood Purif 49:753\u2013757. https:\/\/doi.org\/10.1159\/000506176","journal-title":"Blood Purif"},{"key":"911_CR6","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.3390\/molecules24112062","volume":"24","author":"M Boncler","year":"2019","unstructured":"Boncler\u00a0M, Wu\u00a0Y, Watala\u00a0C (2019) The multiple faces of C\u2011reactive protein\u2014Physiological and pathophysiological implications in cardiovascular disease. Molecules 24:2062. https:\/\/doi.org\/10.3390\/molecules24112062","journal-title":"Molecules"},{"key":"911_CR7","doi-asserted-by":"publisher","first-page":"14188","DOI":"10.1038\/ncomms14188","volume":"8","author":"D Braig","year":"2017","unstructured":"Braig\u00a0D, Nero\u00a0TL, Koch\u00a0H\u2011G et al (2017) Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites. Nat Commun 8:14188. https:\/\/doi.org\/10.1038\/ncomms14188","journal-title":"Nat Commun"},{"key":"911_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/01.CIR.91.2.393","volume":"91","author":"M Buerke","year":"1995","unstructured":"Buerke\u00a0M, Murohara\u00a0T, Lefer\u00a0AM (1995) Cardioprotective effects of a\u00a0C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91:393\u2013402. https:\/\/doi.org\/10.1161\/01.CIR.91.2.393","journal-title":"Circulation"},{"key":"911_CR9","first-page":"429","volume":"286","author":"M Buerke","year":"1998","unstructured":"Buerke\u00a0M, Pr\u00fcfer\u00a0D, Dahm\u00a0M et\u00a0al (1998) Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J\u00a0Pharmacol Exp Ther 286:429\u2013438","journal-title":"J Pharmacol Exp Ther"},{"key":"911_CR10","doi-asserted-by":"publisher","first-page":"5375","DOI":"10.4049\/jimmunol.167.9.5375","volume":"167","author":"M Buerke","year":"2001","unstructured":"Buerke\u00a0M, Schwertz\u00a0H, Seitz\u00a0W et al (2001) Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits. J\u00a0Immunol 167:5375\u20135380. https:\/\/doi.org\/10.4049\/jimmunol.167.9.5375","journal-title":"J Immunol"},{"key":"911_CR11","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen\u00a0G, Wu\u00a0D, Guo\u00a0W et\u00a0al (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J\u00a0Clin Invest 130:2620\u20132629. https:\/\/doi.org\/10.1172\/JCI137244","journal-title":"J Clin Invest"},{"key":"911_CR12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1056\/NEJMoa032804","volume":"350","author":"J Danesh","year":"2004","unstructured":"Danesh\u00a0J, Wheeler\u00a0JG, Hirschfield\u00a0GM et al (2004) C\u2011reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N\u00a0Engl J Med 350:1387\u20131397. https:\/\/doi.org\/10.1056\/NEJMoa032804","journal-title":"N Engl J Med"},{"key":"911_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijsu.2005.04.002","volume":"3","author":"JRS Day","year":"2005","unstructured":"Day\u00a0JRS, Taylor\u00a0KM (2005) The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg 3:129\u2013140. https:\/\/doi.org\/10.1016\/j.ijsu.2005.04.002","journal-title":"Int J Surg"},{"key":"911_CR14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1161\/01.STR.0000165929.78756.ed","volume":"36","author":"M Di Napoli","year":"2005","unstructured":"Di Napoli\u00a0M, Schwaninger\u00a0M, Cappelli\u00a0R et al (2005) Evaluation of C\u2011reactive protein measurement for assessing the risk and prognosis in Ischemic stroke: a statement for health care professionals from the CRP pooling project members. Stroke 36:1316\u20131329. https:\/\/doi.org\/10.1161\/01.STR.0000165929.78756.ed","journal-title":"Stroke"},{"key":"911_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1536\/ihj.47.833","volume":"47","author":"O Dimitrijevi\u0107","year":"2006","unstructured":"Dimitrijevi\u0107\u00a0O, Stojcevski\u00a0BD, Ignjatovi\u0107\u00a0S, Singh\u00a0NM (2006) Serial measurements of C\u2011reactive protein after acute myocardial infarction in predicting one-year outcome. Int Heart\u00a0J 47:833\u2013842","journal-title":"Int Heart J"},{"key":"911_CR16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/01.WCB.0000136517.61642.99","volume":"24","author":"R Gill","year":"2004","unstructured":"Gill\u00a0R, Kemp\u00a0JA, Sabin\u00a0C, Pepys\u00a0MB (2004) Human C\u2011reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J\u00a0Cereb Blood Flow Metab 24:1214\u20131218. https:\/\/doi.org\/10.1097\/01.WCB.0000136517.61642.99","journal-title":"J Cereb Blood Flow Metab"},{"key":"911_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.actbio.2016.10.043","volume":"48","author":"T Goda","year":"2017","unstructured":"Goda\u00a0T, Miyahara\u00a0Y (2017) Calcium-independent binding of human C\u2011reactive protein to lysophosphatidylcholine in supported planar phospholipid monolayers. Acta Biomater 48:206\u2013214. https:\/\/doi.org\/10.1016\/j.actbio.2016.10.043","journal-title":"Acta Biomater"},{"key":"911_CR18","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1084\/jem.190.12.1733","volume":"190","author":"M Griselli","year":"1999","unstructured":"Griselli\u00a0M, Herbert\u00a0J, Hutchinson\u00a0WL et al (1999) C\u2011reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J\u00a0Exp Med 190:1733\u20131740","journal-title":"J Exp Med"},{"key":"911_CR19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nchembio0606-300","volume":"2","author":"JW Heinecke","year":"2006","unstructured":"Heinecke\u00a0JW (2006) Chemical knockout of C\u2011reactive protein in cardiovascular disease. Nat Chem Biol 2:300\u2013301. https:\/\/doi.org\/10.1038\/nchembio0606-300","journal-title":"Nat Chem Biol"},{"key":"911_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijcard.2021.06.023","volume":"338","author":"M Holzknecht","year":"2021","unstructured":"Holzknecht\u00a0M, Tiller\u00a0C, Reindl\u00a0M et al (2021) C\u2011reactive protein velocity predicts microvascular pathology after acute ST-elevation myocardial infarction. Int J Cardiol 338:30\u201336. https:\/\/doi.org\/10.1016\/j.ijcard.2021.06.023","journal-title":"Int J Cardiol"},{"key":"911_CR21","unstructured":"Thielmann\u00a0M (2021) ClinicalTrials.gov Identifier: NCT04898062. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04898062"},{"key":"911_CR22","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1038\/mtna.2012.44","volume":"1","author":"NR Jones","year":"2012","unstructured":"Jones\u00a0NR, Pegues\u00a0MA, McCrory\u00a0MA et al (2012) A selective inhibitor of human C\u2011reactive protein translation is efficacious in vitro and in C\u2011reactive protein transgenic mice and humans. Mol Ther Nucleic Acids 1:e52. https:\/\/doi.org\/10.1038\/mtna.2012.44","journal-title":"Mol Ther Nucleic Acids"},{"key":"911_CR23","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.3390\/jcm9092947","volume":"9","author":"S Kayser","year":"2020","unstructured":"Kayser\u00a0S, Brunner\u00a0P, Althaus\u00a0K et al (2020) Selective apheresis of C\u2011reactive protein for treatment of indications with elevated CRP concentrations. J\u00a0Clin Med 9:2947. https:\/\/doi.org\/10.3390\/jcm9092947","journal-title":"J Clin Med"},{"key":"911_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/1744-9987.13532","volume":"25","author":"S Kayser","year":"2021","unstructured":"Kayser\u00a0S, Kunze\u00a0R, Sheriff\u00a0A (2021) Selective C\u2011reactive protein apheresis for Covid-19\u00a0patients suffering from organ damage. Ther Apher Dial 25:251\u2013252. https:\/\/doi.org\/10.1111\/1744-9987.13532","journal-title":"Ther Apher Dial"},{"key":"911_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMcibr063197","volume":"355","author":"RN Kitsis","year":"2006","unstructured":"Kitsis\u00a0RN, Jialal\u00a0I (2006) Limiting myocardial damage during acute myocardial infarction by inhibiting C\u2011reactive protein. N\u00a0Engl J Med 355:513\u2013515. https:\/\/doi.org\/10.1056\/NEJMcibr063197","journal-title":"N Engl J Med"},{"key":"911_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/01.CIR.99.2.237","volume":"99","author":"W Koenig","year":"1999","unstructured":"Koenig\u00a0W, Sund\u00a0M, Fr\u00f6hlich\u00a0M et al (1999) C\u2011Reactive protein, a\u00a0sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237\u2013242","journal-title":"Circulation"},{"key":"911_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2174\/187152906777441830","volume":"6","author":"P Krijnen","year":"2006","unstructured":"Krijnen\u00a0P, Meischl\u00a0C, Nijmeijer\u00a0R et al (2006) Inhibition of sPLA2-IIA, C\u2011reactive protein or complement: new therapy for patients with acute myocardial infarction? Cardiovasc Hematol Disord Drug Targets 6:111\u2013121. https:\/\/doi.org\/10.2174\/187152906777441830","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"911_CR28","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/1744-9987.12802","volume":"23","author":"R Kunze","year":"2019","unstructured":"Kunze\u00a0R (2019) C\u2011reactive protein: from biomarker to trigger of cell death? Ther Apher Dial 23:494\u2013496. https:\/\/doi.org\/10.1111\/1744-9987.12802","journal-title":"Ther Apher Dial"},{"key":"911_CR29","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.114.6.961","volume":"114","author":"I Kushner","year":"1961","unstructured":"Kushner\u00a0I, Kaplan\u00a0MH (1961) Studies of acute phase protein. J\u00a0Exp Med 114:961\u2013974. https:\/\/doi.org\/10.1084\/jem.114.6.961","journal-title":"J Exp Med"},{"key":"911_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1172\/JCI104715","volume":"42","author":"I Kushner","year":"1963","unstructured":"Kushner\u00a0I, Rakita\u00a0L, Kaplan\u00a0MH (1963) Studies of acute-phase protein. Ii. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. J\u00a0Clin Invest 42:286\u2013292. https:\/\/doi.org\/10.1172\/JCI104715","journal-title":"J Clin Invest"},{"key":"911_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1161\/01.CIR.95.1.97","volume":"95","author":"WK Lagrand","year":"1997","unstructured":"Lagrand\u00a0WK, Niessen\u00a0HW, Wolbink\u00a0GJ et al (1997) C\u2011reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 95:97\u2013103","journal-title":"Circulation"},{"key":"911_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3892\/br.2016.793","volume":"5","author":"D Liu","year":"2016","unstructured":"Liu\u00a0D, Qi\u00a0X, Li\u00a0Q et al (2016) Increased complements and high-sensitivity C\u2011reactive protein predict heart failure in acute myocardial infarction. Biomed Rep 5:761\u2013765. https:\/\/doi.org\/10.3892\/br.2016.793","journal-title":"Biomed Rep"},{"key":"911_CR33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamacardio.2019.0179","volume":"4","author":"P Mani","year":"2019","unstructured":"Mani\u00a0P, Puri\u00a0R, Schwartz\u00a0GG et al (2019) Association of initial and serial C\u2011reactive protein levels with adverse cardiovascular events and death after acute coronary syndrome: a secondary analysis of the VISTA-16 trial. JAMA Cardiol 4:314. https:\/\/doi.org\/10.1001\/jamacardio.2019.0179","journal-title":"JAMA Cardiol"},{"key":"911_CR34","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/1744-9987.12796","volume":"23","author":"S Mattecka","year":"2019","unstructured":"Mattecka\u00a0S, Brunner\u00a0P, H\u00e4hnel\u00a0B et al (2019) PentraSorb C\u2011reactive protein: characterization of the selective C\u2011reactive protein adsorber resin. Ther Apher Dial 23:474\u2013481. https:\/\/doi.org\/10.1111\/1744-9987.12796","journal-title":"Ther Apher Dial"},{"key":"911_CR35","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3389\/fimmu.2018.01351","volume":"9","author":"JD McFadyen","year":"2018","unstructured":"McFadyen\u00a0JD, Kiefer\u00a0J, Braig\u00a0D et al (2018) Dissociation of C\u2011reactive protein localizes and amplifies inflammation: evidence for a\u00a0direct biological role of C\u2011reactive protein and its conformational changes. Front Immunol 9:1351. https:\/\/doi.org\/10.3389\/fimmu.2018.01351","journal-title":"Front Immunol"},{"key":"911_CR36","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1084\/jem.188.12.2313","volume":"188","author":"D Mevorach","year":"1998","unstructured":"Mevorach\u00a0D, Mascarenhas\u00a0JO, Gershov\u00a0D, Elkon\u00a0KB (1998) Complement-dependent clearance of apoptotic cells by human macrophages. J\u00a0Exp Med 188:2313\u20132320. https:\/\/doi.org\/10.1084\/jem.188.12.2313","journal-title":"J Exp Med"},{"key":"911_CR37","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.4049\/jimmunol.168.12.6375","volume":"168","author":"C Mold","year":"2002","unstructured":"Mold\u00a0C, Rodic-Polic\u00a0B, Du Clos\u00a0TW (2002) Protection from Streptococcus pneumoniae infection by C\u2011reactive protein and natural antibody requires complement but not Fc\u03b3 receptors. J\u00a0Immunol 168:6375\u20136381. https:\/\/doi.org\/10.4049\/jimmunol.168.12.6375","journal-title":"J Immunol"},{"key":"911_CR38","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.xcrm.2020.100144","volume":"1","author":"AA Mueller","year":"2020","unstructured":"Mueller\u00a0AA, Tamura\u00a0T, Crowley\u00a0CP et al (2020) Inflammatory biomarker trends predict respiratory decline in COVID-19 patients. Cell Rep Med 1:100144. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100144","journal-title":"Cell Rep Med"},{"key":"911_CR39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/jb\/mvr088","volume":"150","author":"M Murakami","year":"2011","unstructured":"Murakami\u00a0M, Taketomi\u00a0Y, Sato\u00a0H, Yamamoto\u00a0K (2011) Secreted phospholipase A2 revisited. J\u00a0Biochem (Tokyo) 150:233\u2013255. https:\/\/doi.org\/10.1093\/jb\/mvr088","journal-title":"J Biochem (Tokyo)"},{"key":"911_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1749-6632.1982.tb22135.x","volume":"389","author":"AJ Narkates","year":"1982","unstructured":"Narkates\u00a0AJ, Volanakis\u00a0JE (1982) C\u2011reactive protein binding specificities: artificial and natural phospholipid bilayers. Ann N Y Acad Sci 389:172\u2013182. https:\/\/doi.org\/10.1111\/j.1749-6632.1982.tb22135.x","journal-title":"Ann N Y Acad Sci"},{"key":"911_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1423-0127-18-90","volume":"18","author":"MD Neher","year":"2011","unstructured":"Neher\u00a0MD, Weckbach\u00a0S, Flierl\u00a0MA et al (2011) Molecular mechanisms of inflammation and tissue injury after major trauma-is complement the \u201cbad guy\u201d? J\u00a0Biomed Sci 18:90. https:\/\/doi.org\/10.1186\/1423-0127-18-90","journal-title":"J Biomed Sci"},{"key":"911_CR42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/ni.3790","volume":"18","author":"MG Netea","year":"2017","unstructured":"Netea\u00a0MG, Balkwill\u00a0F, Chonchol\u00a0M et\u00a0al (2017) A guiding map for inflammation. Nat Immunol 18:826\u2013831. https:\/\/doi.org\/10.1038\/ni.3790","journal-title":"Nat Immunol"},{"key":"911_CR43","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1038\/s41467-020-18854-2","volume":"11","author":"R Nienhold","year":"2020","unstructured":"Nienhold\u00a0R, Ciani\u00a0Y, Koelzer\u00a0VH et al (2020) Two distinct immunopathological profiles in autopsy lungs of COVID-19. Nat Commun 11:5086. https:\/\/doi.org\/10.1038\/s41467-020-18854-2","journal-title":"Nat Commun"},{"key":"911_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0008-6363(01)00480-1","volume":"53","author":"R Nijmeijer","year":"2002","unstructured":"Nijmeijer\u00a0R (2002) Secretory type II phospholipase A2 binds to ischemic myocardium during myocardial infarction in humans. Cardiovasc Res 53:138\u2013146. https:\/\/doi.org\/10.1016\/S0008-6363(01)00480-1","journal-title":"Cardiovasc Res"},{"key":"911_CR45","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0002-9440(10)63650-4","volume":"163","author":"R Nijmeijer","year":"2003","unstructured":"Nijmeijer\u00a0R, Lagrand\u00a0WK, Lubbers\u00a0YTP et al (2003) C\u2011reactive protein activates complement in infarcted human myocardium. Am J Pathol 163:269\u2013275. https:\/\/doi.org\/10.1016\/S0002-9440(10)63650-4","journal-title":"Am J Pathol"},{"key":"911_CR46","doi-asserted-by":"publisher","first-page":"H2218","DOI":"10.1152\/ajpheart.00887.2002","volume":"285","author":"R Nijmeijer","year":"2003","unstructured":"Nijmeijer\u00a0R, Willemsen\u00a0M, Meijer\u00a0CJLM et\u00a0al (2003) Type II secretory phospholipase A 2 binds to ischemic flip-flopped cardiomyocytes and subsequently induces cell death. Am J Physiol Heart Circ Physiol 285:H2218\u2013H2224. https:\/\/doi.org\/10.1152\/ajpheart.00887.2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"911_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pharmthera.2018.01.001","volume":"186","author":"S-B Ong","year":"2018","unstructured":"Ong\u00a0S\u2011B, Hern\u00e1ndez-Res\u00e9ndiz\u00a0S, Crespo-Avilan\u00a0GE et al (2018) Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther 186:73\u201387. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.01.001","journal-title":"Pharmacol Ther"},{"key":"911_CR48","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0140-6736(81)91565-8","volume":"1","author":"MB Pepys","year":"1981","unstructured":"Pepys\u00a0MB (1981) C\u2011reactive protein fifty years on. Lancet 1:653\u2013657","journal-title":"Lancet"},{"key":"911_CR49","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/nature04672","volume":"440","author":"MB Pepys","year":"2006","unstructured":"Pepys\u00a0MB, Hirschfield\u00a0GM, Tennent\u00a0GA et al (2006) Targeting C\u2011reactive protein for the treatment of cardiovascular disease. Nature 440:1217\u20131221. https:\/\/doi.org\/10.1038\/nature04672","journal-title":"Nature"},{"key":"911_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrcardio.2012.164","volume":"10","author":"SAE Peters","year":"2013","unstructured":"Peters\u00a0SAE, Visseren\u00a0FLJ, Grobbee\u00a0DE (2013) Screening for C\u2011reactive protein in CVD prediction. Nat Rev Cardiol 10:12\u201314. https:\/\/doi.org\/10.1038\/nrcardio.2012.164","journal-title":"Nat Rev Cardiol"},{"key":"911_CR51","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/oxfordjournals.eurheartj.a015068","volume":"17","author":"KO Pietil\u00e4","year":"1996","unstructured":"Pietil\u00e4\u00a0KO, Harmoinen\u00a0AP, Jokiniitty\u00a0J, Pasternack\u00a0AI (1996) Serum C\u2011reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24\u00a0months of follow-up in patients under thrombolytic treatment. Eur Heart\u00a0J 17:1345\u20131349","journal-title":"Eur Heart J"},{"key":"911_CR52","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1177\/2048872616661691","volume":"6","author":"M Reindl","year":"2017","unstructured":"Reindl\u00a0M, Reinstadler\u00a0SJ, Feistritzer\u00a0H\u2011J et al (2017) Relation of inflammatory markers with myocardial and microvascular injury in patients with reperfused ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 6:640\u2013649. https:\/\/doi.org\/10.1177\/2048872616661691","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"911_CR53","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1586\/14779072.2016.1135055","volume":"14","author":"SJ Reinstadler","year":"2016","unstructured":"Reinstadler\u00a0SJ, Stiermaier\u00a0T, Fuernau\u00a0G et al (2016) The challenges and impact of microvascular injury in ST-elevation myocardial infarction. Expert Rev Cardiovasc Ther 14:431\u2013443. https:\/\/doi.org\/10.1586\/14779072.2016.1135055","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"911_CR54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/circ.105.1.2","volume":"105","author":"PM Ridker","year":"2002","unstructured":"Ridker\u00a0PM (2002) On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation 105:2\u20134","journal-title":"Circulation"},{"key":"911_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker\u00a0PM, Cannon\u00a0CP, Morrow\u00a0D et al (2005) C\u2011reactive protein levels and outcomes after statin therapy. N\u00a0Engl J Med 352:20\u201328","journal-title":"N Engl J Med"},{"key":"911_CR56","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker\u00a0PM, MacFadyen\u00a0JG, Everett\u00a0BM et al (2018) Relationship of C\u2011reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a\u00a0secondary analysis from the CANTOS randomised controlled trial. Lancet 391:319\u2013328. https:\/\/doi.org\/10.1016\/S0140-6736(17)32814-3","journal-title":"Lancet"},{"issue":"6","key":"911_CR57","first-page":"23","volume":"21","author":"W Ries","year":"2019","unstructured":"Ries\u00a0W (2019) Die CRP-Apherese: Eine neue Therapiem\u00f6glichkeit bei Inflammation. Nephro-News 21(6):23\u201327","journal-title":"Nephro-News"},{"key":"911_CR58","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/1744-9987.12804","volume":"23","author":"W Ries","year":"2019","unstructured":"Ries\u00a0W, Heigl\u00a0F, Garlichs\u00a0C et al (2019) Selective C\u2011reactive protein-apheresis in patients. Ther Apher Dial 23:570\u2013574. https:\/\/doi.org\/10.1111\/1744-9987.12804","journal-title":"Ther Apher Dial"},{"key":"911_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/4767105","volume":"2018","author":"W Ries","year":"2018","unstructured":"Ries\u00a0W, Sheriff\u00a0A, Heigl\u00a0F et al (2018) \u201cFirst in man\u201d: case report of selective C\u2011reactive protein apheresis in a\u00a0patient with acute ST segment elevation myocardial infarction. Case Rep Cardiol 2018:1\u20134. https:\/\/doi.org\/10.1155\/2018\/4767105","journal-title":"Case Rep Cardiol"},{"key":"911_CR60","doi-asserted-by":"publisher","first-page":"591714","DOI":"10.3389\/fcvm.2021.591714","volume":"8","author":"W Ries","year":"2021","unstructured":"Ries\u00a0W, Torzewski\u00a0J, Heigl\u00a0F et al (2021) C\u2011reactive protein apheresis as anti-inflammatory therapy in acute myocardial infarction: results of the CAMI\u20111 study. Front Cardiovasc Med 8:591714. https:\/\/doi.org\/10.3389\/fcvm.2021.591714","journal-title":"Front Cardiovasc Med"},{"key":"911_CR61","doi-asserted-by":"publisher","first-page":"708101","DOI":"10.3389\/fimmu.2021.708101","volume":"12","author":"J Ringel","year":"2021","unstructured":"Ringel\u00a0J, Ramlow\u00a0A, Bock\u00a0C, Sheriff\u00a0A (2021) Case report: C\u2011reactive protein apheresis in a\u00a0patient with COVID-19 and fulminant CRP increase. Front Immunol 12:708101. https:\/\/doi.org\/10.3389\/fimmu.2021.708101","journal-title":"Front Immunol"},{"key":"911_CR62","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","volume":"46","author":"Q Ruan","year":"2020","unstructured":"Ruan\u00a0Q, Yang\u00a0K, Wang\u00a0W et al (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150\u00a0patients from Wuhan, China. Intensive Care Med 46:846\u2013848. https:\/\/doi.org\/10.1007\/s00134-020-05991-x","journal-title":"Intensive Care Med"},{"key":"911_CR63","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.935263","author":"C Schumann","year":"2021","unstructured":"Schumann\u00a0C, Heigl\u00a0F, Rohrbach\u00a0IJ et al (2021) A report on the first 7 sequential patients treated within the C\u2011reactive protein apheresis in COVID (CACOV) registry. Am J Case Rep. https:\/\/doi.org\/10.12659\/AJCR.935263","journal-title":"Am J Case Rep"},{"key":"911_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/jca.21344","volume":"30","author":"A Sheriff","year":"2015","unstructured":"Sheriff\u00a0A, Schindler\u00a0R, Vogt\u00a0B et al (2015) Selective apheresis of C\u2011reactive protein: A new therapeutic option in myocardial infarction?: Selective CRP-apheresis. J\u00a0Clin Apheresis 30:15\u201321. https:\/\/doi.org\/10.1002\/jca\u00a0.21344","journal-title":"J Clin Apheresis"},{"key":"911_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000320763","volume":"31","author":"AC Slagman","year":"2011","unstructured":"Slagman\u00a0AC, Bock\u00a0C, Abdel-Aty\u00a0H et al (2011) Specific removal of C\u2011reactive protein by apheresis in a\u00a0porcine cardiac infarction model. Blood Purif 31:9\u201317. https:\/\/doi.org\/10.1159\/000320763","journal-title":"Blood Purif"},{"key":"911_CR66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4049\/jimmunol.182.1.39","volume":"182","author":"BL Sparkes","year":"2009","unstructured":"Sparkes\u00a0BL, Woods\u00a0K, Roth\u00a0M et\u00a0al (2009) Phospholipase A2 alters membrane lipid composition during ischemia\/reperfusion (39.55). J\u00a0Immunol 182:39\u201355","journal-title":"J Immunol"},{"key":"911_CR67","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","volume":"9","author":"NR Sproston","year":"2018","unstructured":"Sproston\u00a0NR, Ashworth\u00a0JJ (2018) Role of C\u2011reactive protein at sites of inflammation and infection. Front Immunol 9:754. https:\/\/doi.org\/10.3389\/fimmu.2018.00754","journal-title":"Front Immunol"},{"key":"911_CR68","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","volume":"67","author":"GW Stone","year":"2016","unstructured":"Stone\u00a0GW, Selker\u00a0HP, Thiele\u00a0H et\u00a0al (2016) Relationship between infarct size and outcomes following primary PCI. J\u00a0Am Coll Cardiol 67:1674\u20131683. https:\/\/doi.org\/10.1016\/j.jacc.2016.01.069","journal-title":"J Am Coll Cardiol"},{"key":"911_CR69","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.5114\/aoms.2017.69327","volume":"5","author":"C Stumpf","year":"2017","unstructured":"Stumpf\u00a0C, Sheriff\u00a0A, Zimmermann\u00a0S et al (2017) C\u2011reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty. Arch Med Sci 5:1086\u20131093. https:\/\/doi.org\/10.5114\/aoms.2017.69327","journal-title":"Arch Med Sci"},{"key":"911_CR70","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jacc.2005.10.055","volume":"47","author":"M Suleiman","year":"2006","unstructured":"Suleiman\u00a0M, Khatib\u00a0R, Agmon\u00a0Y et al (2006) Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C\u2011reactive protein. J\u00a0Am Coll Cardiol 47:962\u2013968. https:\/\/doi.org\/10.1016\/j.jacc.2005.10.055","journal-title":"J Am Coll Cardiol"},{"key":"911_CR71","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1128\/iai.64.11.4850-4853.1996","volume":"64","author":"AJ Szalai","year":"1996","unstructured":"Szalai\u00a0AJ, Briles\u00a0DE, Volanakis\u00a0JE (1996) Role of complement in C\u2011reactive-protein-mediated protection of mice from streptococcus pneumoniae. Infect Immun 64:4850\u20134853. https:\/\/doi.org\/10.1128\/iai.64.11.4850-4853.1996","journal-title":"Infect Immun"},{"key":"911_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/353614","volume":"2014","author":"AJ Szalai","year":"2014","unstructured":"Szalai\u00a0AJ, McCrory\u00a0MA, Xing\u00a0D et al (2014) Inhibiting C\u2011reactive protein for the treatment of cardiovascular disease: promising evidence from rodent models. Mediators Inflamm 2014:1\u20139. https:\/\/doi.org\/10.1155\/2014\/353614","journal-title":"Mediators Inflamm"},{"key":"911_CR73","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/jmv.25871","volume":"92","author":"C Tan","year":"2020","unstructured":"Tan\u00a0C, Huang\u00a0Y, Shi\u00a0F et al (2020) C\u2011reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J\u00a0Med Virol 92:856\u2013862. https:\/\/doi.org\/10.1002\/jmv.25871","journal-title":"J Med Virol"},{"key":"911_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/372432","volume":"2015","author":"JR Thiele","year":"2015","unstructured":"Thiele\u00a0JR, Zeller\u00a0J, Bannasch\u00a0H et al (2015) Targeting C\u2011reactive protein in inflammatory disease by preventing conformational changes. Mediators Inflamm 2015:1\u20139. https:\/\/doi.org\/10.1155\/2015\/372432","journal-title":"Mediators Inflamm"},{"key":"911_CR75","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ijcard.2020.12.006","volume":"328","author":"C Tiller","year":"2021","unstructured":"Tiller\u00a0C, Reindl\u00a0M, Holzknecht\u00a0M et al (2021) High sensitivity C\u2011reactive protein is associated with worse infarct healing after revascularized ST-elevation myocardial infarction. Int J Cardiol 328:191\u2013196. https:\/\/doi.org\/10.1016\/j.ijcard.2020.12.006","journal-title":"Int J Cardiol"},{"key":"911_CR76","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1084\/jem.52.4.561","volume":"52","author":"WS Tillett","year":"1930","unstructured":"Tillett\u00a0WS, Francis\u00a0T (1930) Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J\u00a0Exp Med 52:561\u2013571","journal-title":"J Exp Med"},{"key":"911_CR77","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.925020","author":"J Torzewski","year":"2020","unstructured":"Torzewski\u00a0J, Heigl\u00a0F, Zimmermann\u00a0O et al (2020) First-in-man: case report of selective C\u2011reactive protein apheresis in a\u00a0patient with SARS-CoV\u20112 infection. Am J Case Rep. https:\/\/doi.org\/10.12659\/AJCR.925020","journal-title":"Am J Case Rep"},{"key":"911_CR78","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.932964","author":"J Torzewski","year":"2021","unstructured":"Torzewski\u00a0J, Zimmermann\u00a0O, Kayser\u00a0S et al (2021) Successful treatment of a\u00a039-year-old COVID-19\u00a0patient with respiratory failure by selective C\u2011reactive protein apheresis. Am J Case Rep. https:\/\/doi.org\/10.12659\/AJCR.932964","journal-title":"Am J Case Rep"},{"key":"911_CR79","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.lfs.2003.12.029","volume":"75","author":"A Valtchanova-Matchouganska","year":"2004","unstructured":"Valtchanova-Matchouganska\u00a0A, Gondwe\u00a0M, Nadar\u00a0A (2004) The role of C\u2011reactive protein in ischemia\/reperfusion injury and preconditioning in a\u00a0rat model of myocardial infarction. Life Sci 75:901\u2013910. https:\/\/doi.org\/10.1016\/j.lfs.2003.12.029","journal-title":"Life Sci"},{"key":"911_CR80","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/08916930701358925","volume":"40","author":"B Vogt","year":"2007","unstructured":"Vogt\u00a0B, F\u00fchrnrohr\u00a0B, M\u00fcller\u00a0R, Sheriff\u00a0A (2007) CRP and the disposal of dying cells: consequences for systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity 40:295\u2013298","journal-title":"Autoimmunity"},{"key":"911_CR81","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1126\/science.368.6489.356","volume":"368","author":"M Wadman","year":"2020","unstructured":"Wadman\u00a0M, Couzin-Frankel\u00a0J, Kaiser\u00a0J, Matacic\u00a0C (2020) A rampage through the body. Science 368:356\u2013360. https:\/\/doi.org\/10.1126\/science.368.6489.356","journal-title":"Science"},{"key":"911_CR82","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1093\/eurheartj\/ehx414","volume":"38","author":"S de Waha","year":"2017","unstructured":"de Waha\u00a0S, Patel\u00a0MR, Granger\u00a0CB et al (2017) Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. Eur Heart\u00a0J 38:3502\u20133510. https:\/\/doi.org\/10.1093\/eurheartj\/ehx414","journal-title":"Eur Heart J"},{"key":"911_CR83","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s12035-013-8565-9","volume":"49","author":"T Yagami","year":"2014","unstructured":"Yagami\u00a0T, Yamamoto\u00a0Y, Koma\u00a0H (2014) The role of secretory phospholipase A2 in the central nervous system and neurological diseases. Mol Neurobiol 49:863\u2013876. https:\/\/doi.org\/10.1007\/s12035-013-8565-9","journal-title":"Mol Neurobiol"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-022-00911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00063-022-00911-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-022-00911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T02:19:43Z","timestamp":1649211583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00063-022-00911-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["911"],"URL":"https:\/\/doi.org\/10.1007\/s00063-022-00911-x","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"assertion":[{"value":"25 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Buerke, A.\u00a0Sheriff und C.D.\u00a0Garlichs geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}